| | By Gabrielle Masson,Darren Incorvaia The National Institutes of Health is rolling out rules that block new grants for any researcher or institution advancing programs related to diversity, equity and inclusion. |
|
|
|
By Gabrielle Masson,Darren Incorvaia The National Institutes of Health (NIH) is halting new grant and contract payments to several universities, a move the agency has been instructed not to disclose to the affected schools, according to several reports. |
By Kevin Dunleavy Revenues boomed for the top 20 companies in the biopharma industry in 2024, with only one company (Bayer) seeing a revenue decline last year. Six drugmakers saw their sales rise by double-digit percentages, led by Eli Lilly (32%) and Novo Nordisk (26%). |
By Gabrielle Masson Employees of companies regulated by the FDA—such as pharmas or biotechs—are no longer allowed to serve as members of FDA advisory committees, according to a new directive from the agency's commissioner. |
By Andrea Park OPDP director Catherine Gray and deputy director Mark Askine told staffers on Thursday that they were leaving, and their resignations took effect Friday, Politico’s AgencyIQ reports, citing emails shared by sources within the office. |
By Darren Incorvaia The Department of Health and Human Services is cutting off funding to the long-running Women’s Health Initiative in September, a move that leaves the fate of one of the world's largest women’s health studies hanging in the balance. |
By Kevin Dunleavy Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment Wegovy, Novo Nordisk has asked the FDA to approve it. |
By Angus Liu Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of exclusivity, has hit a phase 3 setback. |
By Nick Paul Taylor Alis Biosciences has made a pitch to the hundreds of biotechs that are valued at less than the cash they have in the bank. The investment fund is proposing to buy the companies and return most of their cash to shareholders, offering them an alternative to exits such as reverse mergers and liquidations. |
By Zoey Becker The Swiss pharma's sweeping $50 billion investment comes as the threat of U.S. tariffs on pharmaceuticals continues to loom over the biopharma industry. |
By Conor Hale Biolinq's coin-sized device, worn on the forearm, can also track sleep and activity data to help provide additional context around the user’s metabolic health. |
Fierce podcastsDon’t miss an episode |
| | This week on "Podnosis," Yumlish CEO Shireen Abdullah joins us to discuss how culturally tailored nutrition education is helping tackle diabetes—and why looming federal budget cuts could derail that progress. |
|
|---|
|
|
|
Tuesday, May 6, 2025 | 9am ET / 6am PT This webinar will explore how to use AI-driven tools for timely data-driven decisions that are critical to securing approvals, expediting market entry and sustaining competitive strength. Register now.
|
|
| eBookTypical vaccine development timelines have averaged 10 years, but the time from the SARS-CoV-2 genetic sequence’s release to the submission of the first vaccine clinical trial data for regulatory review was a mere 314 days. In IQVIA Laboratories’ Vaccine eBook we focus on how contract research organizations (CROs) can best leverage strategic partnerships with sponsors to prepare for the next pandemic. Sponsored by: IQVIA |
| WhitepaperIs your clinical trial data truly reliable? Learn how a combined approach using Imaging Core Labs and Endpoint Adjudication Committees (EAC) can minimize risk, control costs, and strengthen your study from the ground up. Don’t leave success to chance—arm yourself with the insights to stay ahead. Sponsored by: WCG |
| ResearchWe interviewed 15 biopharma leaders on the critical success factors for building a Best Practice customer-facing organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
